Roberto De Haro-Hernández1, Lourdes Cabrera-Muñoz, José D Méndez. 1. Unidad de Investigación Médica en Enfermedades Metabólicas, Departamento de Patología Anatómica, Hospital de Especialidades, Centro Meédico Nacional Siglo XXI (CMN-SXXI), IMSS, Mexico City, 06703 Mexico.
Abstract
BACKGROUND: We previously showed by using biochemical parameters that male Sprague-Dawley rats receiving a single intraperitoneal (i.p.) administration of alloxan (120 mg/kg body weight) with no further treatment recovered endocrine pancreatic function after 12 days. METHODS: Male Sprague-Dawley rats received an i.p. injection of alloxan (120 mg/kg body wt), were killed at 3, 6, 9, or 12 days (n=7), and their capacity to recover endocrine function was evaluated by means of a) biochemical parameters, which included glucose, triglyceride, and total cholesterol measurements and b) nuclear incorporation of 5'-bromodeoxyuridine (BrdU) by beta and acinar cells as well as presence of neogenesis from either ductal or acinar cells using double-staining BrdU-insulin immunohistochemical technique. RESULTS: Three days after receiving a single i.p. administration of alloxan, rats showed increase in serum glucose, triglyceride, and total cholesterol concentrations, reaching levels of 542.4+/-63.1, 907.6+/-154.9, and 106.0+/-2.7 mg/dL (mean+/-standard deviation [SD]), respectively. At this time, increase in beta-cell replication was also observed, although this reached maximum by day 6 (p <0.001). Replication was also present in acinar cells, but these cells showed their maximum at day 3 (p <0.001) and subsequently decreased, as did beta-cells, almost steadily to normal values by day 12. Neogenesis of beta-cells was observed mainly as transdifferentiation from acinar cells at day 3 and from ductal cells at day 6, after which it tended to be normal. CONCLUSIONS: Male Sprague-Dawley rats receiving a single i.p. alloxan dose tended to normalize their endocrine function by day 12 after alloxan administration. This process included both regeneration and neogenesis of pancreatic beta-cells from either ductal or acinar cells.
BACKGROUND: We previously showed by using biochemical parameters that male Sprague-Dawley rats receiving a single intraperitoneal (i.p.) administration of alloxan (120 mg/kg body weight) with no further treatment recovered endocrine pancreatic function after 12 days. METHODS: Male Sprague-Dawley rats received an i.p. injection of alloxan (120 mg/kg body wt), were killed at 3, 6, 9, or 12 days (n=7), and their capacity to recover endocrine function was evaluated by means of a) biochemical parameters, which included glucose, triglyceride, and total cholesterol measurements and b) nuclear incorporation of 5'-bromodeoxyuridine (BrdU) by beta and acinar cells as well as presence of neogenesis from either ductal or acinar cells using double-staining BrdU-insulin immunohistochemical technique. RESULTS: Three days after receiving a single i.p. administration of alloxan, rats showed increase in serum glucose, triglyceride, and total cholesterol concentrations, reaching levels of 542.4+/-63.1, 907.6+/-154.9, and 106.0+/-2.7 mg/dL (mean+/-standard deviation [SD]), respectively. At this time, increase in beta-cell replication was also observed, although this reached maximum by day 6 (p <0.001). Replication was also present in acinar cells, but these cells showed their maximum at day 3 (p <0.001) and subsequently decreased, as did beta-cells, almost steadily to normal values by day 12. Neogenesis of beta-cells was observed mainly as transdifferentiation from acinar cells at day 3 and from ductal cells at day 6, after which it tended to be normal. CONCLUSIONS: Male Sprague-Dawley rats receiving a single i.p. alloxan dose tended to normalize their endocrine function by day 12 after alloxan administration. This process included both regeneration and neogenesis of pancreatic beta-cells from either ductal or acinar cells.
Authors: Bhavna Bharucha; Malati Umarani; Mitesh Dwivedi; Naresh C Laddha; Rasheedunnisa Begum; Anandwardhan A Hardikar; A V Ramachandran Journal: Evid Based Complement Alternat Med Date: 2012-02-27 Impact factor: 2.629
Authors: Heike Immervoll; Dag Hoem; Per Øystein Sakariassen; Ole Johnny Steffensen; Anders Molven Journal: BMC Cancer Date: 2008-02-08 Impact factor: 4.430
Authors: Glauce S B Viana; Ana Carolina C Medeiros; Ana Michelle R Lacerda; L Kalyne A M Leal; Tiago G Vale; F José De Abreu Matos Journal: BMC Pharmacol Date: 2004-06-08
Authors: Chiara Toselli; Colin M Hyslop; Martha Hughes; David R Natale; Pere Santamaria; Carol T L Huang Journal: PLoS One Date: 2014-06-18 Impact factor: 3.240